Funding Support and Author Disclosures Dr Ben-Chetrit has received lecture fees from Sobi and Novartis (anti-Il-1 inhibitors in autoinflammatory diseases). Dr Falk has served as a consultant to Alnylam Pharmaceuticals and Alexion; and serves on data monitoring committees for Novo Nordisk and Alexion. Dr Ridker has received institutional research grant support from the National Heart, Lung, and Blood Institute, Novartis, and Novo Nordisk (to evaluate the role of anti-inflammatory agents including methotrexate, interleukin-1 inhibitors, and interleukin-6 inhibitors) as well as Kowa, Amarin, Pfizer, and Esperion; has served as a consultant to Novartis, Novo Nordisk, Janssen, Flame, Agepha, Ardelyx, Zomagen, Horizon Therapeutics, CSL Behring, and Cardio Therapeutics (entities developing anti-inflammatory therapies including as examples colchicine, interleukin-1 inhibitors, interleukin-6 inhibitors, and agents that potentially target or interact with the NLRP3 inflammasome); has served as a consultant to AstraZeneca, Civi Biopharm, GlaxoSmithKline, SOCAR, Health Outlook, Montai Health, Eli Lilly, New Amsterdam, Boehringer Ingelheim, RTI, and Cytokinetics; has minority shareholder equity positions in Uppton, Bitteroot Bio, and Angiowave; and receives compensation for service on the Peter Munk Advisory Board (University of Toronto), the Leducq Foundation, Paris FR, and the Baim Institute. Dr Nidorf has reported that he has no relationships relevant to the contents of this paper to disclose.